AbeXXa Biologics

AbeXXa Biologics is a biotechnology company specializing in the discovery and development of next-generation cancer immunotherapies that target the "dark matter" of the cancer genome. The company's proprietary platform identifies peptides derived from intracellular proteins that are presented on the cell surface by Major Histocompatibility Complex (MHC) molecules. By leveraging T-cell receptor-like (TCR-like) antibodies, AbeXXa creates therapies that can recognize these previously undruggable intracellular targets with high specificity. In September 2021, the company was acquired by Boehringer Ingelheim to integrate its novel antigen-targeting capabilities into the global pharmaceutical leader's oncology portfolio. AbeXXa continues to operate as a key innovation hub for developing precision medicines for patients with hard-to-treat solid tumors.